Intended for healthcare professionals

CCBYNC Open access

Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis

BMJ 2019; 366 doi: (Published 18 September 2019) Cite this as: BMJ 2019;366:l5221

Linked Editorial

Flawed evidence underpins approval of new cancer drugs

Linked Opinion

Gauging the validity of cancer drug trials: a call for collaboration